Results 151 to 160 of about 6,192 (194)

SMPDL3B a novel biomarker and therapeutic target in myalgic encephalomyelitis. [PDF]

J Transl Med
Rostami-Afshari B, Elremaly W, Franco A, Elbakry M, Akoume MY, Boufaied I, Moezzi A, Leveau C, Rompré P, Godbout C, Mella O, Fluge Ø, Moreau A.   +12 more
europepmc   +1 more source

DPP-4 Inhibitors in Female Cancers: Opportunities for Drug Repurposing. [PDF]

Curr Issues Mol Biol
Muddather HF, Schelz Z, Zupkó I.
europepmc   +1 more source

Vildagliptin and its Association with Bullous Pemphigoid.

Ann Afr Med
Meah A, Reddy KS, Rajeshwari KA.
europepmc   +1 more source

Comparative Efficacy, Safety, and Cost-Utility of DPP-4 Inhibitors and Metformin Combination Therapy in Type 2 Diabetes: A Systematic Review of Real-World Clinical and Economic Outcomes. [PDF]

J Diabetes Res
Jimoh AO, Hudu SA, Sabir AA, Adamu AA, Bello N, Tahir A, Abubakar N.   +6 more
europepmc   +1 more source

Identification, Isolation and Structural Elucidation of New Inner Salt Impurity in Vildagliptin and Metformin Tablet by Using Supercritical Fluid Chromatography, NMR, HRMS. [PDF]

J Sep Sci
Meganathan SK, Sahoo BK, Reddy YR, Rajani K, Reddy PR.   +4 more
europepmc   +1 more source

Dual therapy with vildagliptin and sacubitril/valsartan alleviates portal hypertension and inhibits soluble epoxide hydrolase in cirrhotic rats. [PDF]

World J Gastroenterol
Oyama M, Kaji K, Nishimura N, Hanatani J, Nakatani T, Nishimura N, Shibamoto A, Asada S, Tsuji Y, Kitagawa K, Sato S, Namisaki T, Yoshiji H.   +12 more
europepmc   +1 more source

Correction: SMPDL3B a novel biomarker and therapeutic target in myalgic encephalomyelitis. [PDF]

J Transl Med
Rostami-Afshari B, Elremaly W, Franco A, Elbakry M, Akoume MY, Boufaied I, Moezzi A, Leveau C, Rompré P, Godbout C, Mella O, Fluge Ø, Moreau A.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Vildagliptin

Drugs, 2006
Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that is being evaluated in the treatment of patients with type 2 diabetes mellitus. It improves glycaemic control by inhibiting DPP-4 from inactivating the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, prolonging incretin activity in response to ...
Sheridan, Henness, Susan J, Keam
  +6 more sources

Vildagliptin

Drugs, 2012
Susan J Keam, Keam Susan J
exaly   +2 more sources